Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing

30 Aug 2024

Abstract excerpt

Mutations in the BRCA1 and/or BRCA2 genes (BRCAm) increase the risk of developing breast cancer (BC) and are found in ~5% of unselected patients with the disease. BC resulting from a germline BRCAm (gBRCAm) has distinct clinical characteristics along with increased sensitivity to DNA-damaging agents such as poly(ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies, and potentially decreased...

Topics

Join the communities discussing this publication.

BRCA gene mutations in cancer
Cancer Genomics and Diagnostics
PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39215191
DOI: 10.1038/s41416-024-02827-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testingPMID 39215191Read ↗

Prevention, diagnosis and clinical management of hereditary breast cancer beyond BRCA1/2 genes.Semantic proximity Read ↗

Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Semantic proximity Read ↗

Genetic testing in women with breast cancer: implications for treatment.Semantic proximity Read ↗

Genetic Signature of Breast Cancer Defines Therapeutic Interventions and Indicates Early Drug Resistance.Semantic proximity Read ↗

Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management.Semantic proximity Read ↗

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.Semantic proximity Read ↗

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.Semantic proximity Read ↗

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline VariantsSemantic proximity Read ↗

Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific TreatmentsSemantic proximity Read ↗

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast CancerSemantic proximity Read ↗

Pathogenic variants among females with breast cancer and a non-breast cancer reveal opportunities for cancer interception.Semantic proximity Read ↗

Predictive Value and Therapeutic Significance of Somatic BRCA Mutation in Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.